| 1 | Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment. 2020;16:62 doi: 10.2174/1573394715666190913184853 |
| 2 | Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. 2019;90:138 doi: 10.1007/s00115-018-0571-8 |
| 3 | Cell density quantification with TurboSPI: R2* mapping with compensation for off-resonance fat modulation. 2020;33:469 doi: 10.1007/s10334-019-00817-4 |
| 4 | Exploiting Cancer’s Tactics to Make Cancer a Manageable Chronic Disease. 2020;12:1649 doi: 10.3390/cancers12061649 |
| 5 | Immunotherapy. 2020;1244:255 doi: 10.1007/978-3-030-41008-7_13 |
| 6 | Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. 2020;6:29 doi: 10.1007/s40883-019-00113-6 |
| 7 | Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas. 2020;12:432 doi: 10.3390/cancers12020432 |
| 8 | . 2020; doi: 10.1007/5584_2020_522 |
| 9 | Reference Module in Biomedical Sciences. 2020; doi: 10.1016/B978-0-12-801238-3.11605-8 |
| 10 | Bovine Dialyzable Leukocyte Extract IMMUNEPOTENT-CRP Induces Selective ROS-Dependent Apoptosis in T-Acute Lymphoblastic Leukemia Cell Lines. 2020;2020:1 doi: 10.1155/2020/1598503 |
| 11 | The emergence of drug resistance to targeted cancer therapies: Clinical evidence. 2019;47:100646 doi: 10.1016/j.drup.2019.100646 |
| 12 | Immunotherapy. 2018;995:131 doi: 10.1007/978-3-030-02505-2_6 |
| 13 | Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. 2018;50: doi: 10.1038/s12276-018-0115-0 |
| 14 | Recent advances in localized immunotherapy of skin cancers. 2019;11:443 doi: 10.2217/imt-2018-0139 |
| 15 | Principles of Tumors. 2020;453 doi: 10.1016/B978-0-12-816920-9.00018-3 |
| 16 | CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. 2018;6:105 doi: 10.3390/biomedicines6040105 |
| 17 | Bioactive Nanoparticles for Cancer Immunotherapy. 2018;19:3877 doi: 10.3390/ijms19123877 |
| 18 | MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. 2019;303:223 doi: 10.1016/j.jconrel.2019.04.019 |
| 19 | Checkpoint inhibitors: What gastroenterologists need to know. 2018;24:5433 doi: 10.3748/wjg.v24.i48.5433 |
| 20 | Peptide-based targeting of immunosuppressive cells in cancer. 2020;5:92 doi: 10.1016/j.bioactmat.2020.01.006 |
| 21 | Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments. 2020;1 doi: 10.1080/08820139.2020.1748047 |
| 22 | Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. 2020;106:104722 doi: 10.1016/j.oraloncology.2020.104722 |
| 23 | Editorial. 2019;12:3 doi: 10.1111/ors.12402 |
| 24 | Active immunotherapy of cancer: An overview of therapeutic vaccines. 2019;69:490 doi: 10.5937/arhfarm1906490F |
| 25 | Combined strategies for tumor immunotherapy with nanoparticles. 2019;21:1441 doi: 10.1007/s12094-019-02081-3 |
| 26 | Biomaterials for Cancer Therapeutics. 2020;331 doi: 10.1016/B978-0-08-102983-1.00012-0 |
| 27 | Modeling immune cell behavior across scales in cancer. 2020;12:e1484 doi: 10.1002/wsbm.1484 |
| 28 | Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. 2019;11:248 doi: 10.1007/s12609-019-00332-4 |
| 29 | Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. 2019;9: doi: 10.3389/fonc.2019.00396 |
| 30 | Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. 2020;37:354 doi: 10.1016/j.ccell.2020.02.001 |
| 31 | Immunotherapy and other systemic therapies for cutaneous SCC. 2019;99:104459 doi: 10.1016/j.oraloncology.2019.104459 |
| 32 | Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab. 2020;7:7 doi: 10.2217/mmt-2019-0020 |
| 33 | O-acetylated Gangliosides as Targets for Cancer Immunotherapy. 2020;9:741 doi: 10.3390/cells9030741 |
| 34 | Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. 2020;20: doi: 10.1186/s12874-020-00997-x |
| 35 | Cancer and the Immune System: The History and Background of Immunotherapy. 2019;35:150923 doi: 10.1016/j.soncn.2019.08.002 |
| 36 | The need for rapid therapeutic efficacy testing for cancer therapy. 2020;113:104382 doi: 10.1016/j.yexmp.2020.104382 |
| 37 | Integrative Nanomedicine for New Therapies. 2020;321 doi: 10.1007/978-3-030-36260-7_12 |
| 38 | Emerging therapeutic agents for advanced non-small cell lung cancer. 2020;13: doi: 10.1186/s13045-020-00881-7 |
| 39 | The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. 2020;10:666 doi: 10.3390/biom10050666 |
| 40 | Molecular and Cell Biology of Cancer. 2019;117 doi: 10.1007/978-3-030-11812-9_7 |
| 41 | Novel therapeutic strategies for spinal osteosarcomas. 2020;64:83 doi: 10.1016/j.semcancer.2019.05.018 |
| 42 | Current Applications for Overcoming Resistance to Targeted Therapies. 2019;20:97 doi: 10.1007/978-3-030-21477-7_4 |
| 43 | Cancer: The Enemy from Within. 2020;223 doi: 10.1007/978-3-030-40651-6_9 |
| 44 | Learning-accelerated discovery of immune-tumour interactions. 2019;4:747 doi: 10.1039/C9ME00036D |
| 45 | Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. 2020;112:562 doi: 10.1093/jnci/djaa021 |
| 46 | The Microbiome in Health and Disease. 2020;171:301 doi: 10.1016/bs.pmbts.2020.04.004 |
| 47 | Resistance to Targeted Therapies in Lymphomas. 2019;21:155 doi: 10.1007/978-3-030-24424-8_7 |
| 48 | A guide to cancer immunotherapy: from T cell basic science to clinical practice. 2020; doi: 10.1038/s41577-020-0306-5 |
| 49 | CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. 2020;19:191 doi: 10.1093/bfgp/elz039 |
| 50 | Current trends in cancer immunotherapy: a literature-mining analysis. 2020; doi: 10.1007/s00262-020-02630-8 |
| 51 | Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. 2019;19:2158 doi: 10.2174/1568026619666190904163524 |
| 52 | Nanoparticles: Properties and Applications in Cancer Immunotherapy. 2019;25:1962 doi: 10.2174/1381612825666190708214240 |
| 53 | The Intriguing History of Cancer Immunotherapy. 2019;10: doi: 10.3389/fimmu.2019.02965 |